Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc Receives Marketing Authorization for VESOMNI from The Netherlands Medicines Evaluation Board


Thursday, 23 May 2013 03:00am EDT 

ASTELLAS PHARMA EUROPE B.V., the European subsidiary of Astellas Pharma Inc., announced the Dutch Medicines Evaluation Board (MEB) has granted marketing authorization for VESOMNI in the Netherlands. The market authorization granted for VESOMNI is for ‚Äútreatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy. 

Company Quote

1702.5
47.5 +2.87%
19 Dec 2014